SCHEMBL3937064

SCHEMBL3937064

COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccc2c(c1)OC=CO2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
CASP1 P29466 1/20 0.36
ALOX5 P09917 1/20 0.35
ROCK2 O75116 5/20 0.35
SMN1; SMN2 Q16637 4/20 0.34
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
CASP3 P42574 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
CYP3A4 P08684 2/20 0.34
MAPT P10636 3/20 0.33
CYP2C19 P33261 1/20 0.33
LSS P48449 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3937069 1.00 KMT2A (0.36) KMT2ACTDSP1CASP1ALOX5ROCK2
SCHEMBL3935237 0.92 MAPT (0.40) KMT2ACTDSP1CASP1ALOX5SMN1; SMN2
SCHEMBL3935228 0.92 MAPT (0.40) KMT2ACTDSP1CASP1ALOX5SMN1; SMN2
SCHEMBL3942797 0.89 RAB9A (0.48) KMT2ASMN1; SMN2RAB9ANPC1CASP3
SCHEMBL3933786 0.89 MEN1 (0.43) KMT2ASMN1; SMN2RAB9ANPC1CASP3
SCHEMBL3933791 0.89 MEN1 (0.43) KMT2ASMN1; SMN2RAB9ANPC1CASP3
SCHEMBL3942795 0.89 RAB9A (0.48) KMT2ASMN1; SMN2RAB9ANPC1CASP3
SCHEMBL3935543 0.89 LSS (0.39) ROCK2SMN1; SMN2PSEN1PSEN2APH1B
SCHEMBL5858220 0.89 BACE1 (0.37) ROCK2SMN1; SMN2CASP3MAPTLSS
SCHEMBL3939851 0.89 BACE1 (0.37) ROCK2SMN1; SMN2CASP3MAPTLSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 KMT2A 1839/4885CTDSP1 673/4885CASP1 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.